BackRepligen Overview

Repligen Current Cash

Repligen's current cash is $610M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$606.78M
14.40% YoYΔ $-102.07M vs prior year quarter

Peer average

Loading

Repligen Current Cash History

Loading

Repligen vs. peers: Current Cash Comparison

Loading

Repligen Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Repligen (RGEN) FAQ

As of the most recent data (June 2026), RGEN shows a current cash of $610M. That compares with $710M in the prior-year period — down 14.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RGEN's current cash is now $610M (was $710M) — a 14.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Repligen is outperforming or lagging.

Tracking RGEN's current cash over time shows whether Repligen is scaling, shrinking, or reshaping that part of the business. The current reading is $610M That compares with $710M in the prior-year period — down 14.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Repligen's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $610M) with ownership activity and broader fundamentals.

Repligen's current cash is $610M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.